OBJECTIVES: The aim of the study was to evaluate the immune status of young people from the Vojvodina province, Serbia, through the detection of IgG antibodies specific for the L1 protein of HPV types 6, 11, 16, and 18 contained in quadrivalent vaccine. METHODS: The study enrolled 514 healthy persons of both genders, aged between 18 and 30 years. All potential participants were informed about the project's aims by trained interviewers before venous blood collection. Also, participants completed a specially designed anonymous questionnaire to identify socio-demographic characteristics and individual behaviours associated with HPV seroprevalence. VPL HPV L1-specific IgG antibodies were measured using a semi-quantitative HPV IgG ELISA kit (Dia.Pro, Italy). RESULTS: A total of 472 (91.8%) young subjects had no detectable antibodies against high- and low-risk HPV types covered by the quadrivalent vaccine. A slightly higher number of seropositive individuals were detected in the age group of 26-30 years compared to younger than 25. Multivariate analysis showed that the number of lifetime sexual partners was the most powerful predictor of HPV seropositivity (OR = 3.483, 95% CI: 1.294-9.379). CONCLUSIONS: Obtained data point out low levels of naturally induced HPV-specific serum antibodies among the target population in the Vojvodina province. The present work highlights the significance and potential benefits of HPV vaccination. Routine HPV vaccination should be the public health priority in our country and should be included in the national immunization programme as soon as possible.

Centre of Virology Institute for Public Health of Vojvodina Novi Sad Serbia

Faculty of Biology University of Belgrade Belgrade Serbia

Faculty of Medicine University of Novi Sad Novi Sad Serbia

See more in PubMed

Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination - review of current perspectives. J Oncol. 2019;2019:3257939. doi: 10.1155/2019/3257939. PubMed DOI

Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513-7. DOI

de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-70. DOI

Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-22.

Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911-9.

Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003;89(7):1248-54. DOI

Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol. 1998;36(7):2046-51. DOI

Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis. 2008;46(11):1647-55.

Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009;200(7):1059-67. DOI

Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, et al. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis. 2011;38(10):976-82. DOI

Adekunle S, Sule WF, Oluwayelu DO. High negativity of IgG antibodies against human papillomavirus type 6, 11, 16 and 18 virus-like particles in healthy women of childbearing age. J Exp Integr Med. 2014;4(1):37-41. DOI

Knežević A, Aleksić G, Soldatović I,Banko A, Jovanović T. Cervical human papillomavirus infection in Serbia: risk factors, prevalence and genotype distribution in women with normal cervical cytology. Arch Biol Sci. 2012;64(4):1277-83. DOI

Kovacevic G, Milosevic V, Nikolic N, Patic A, Dopudj N, Radovanov J, et al. The prevalence of 30 HPV genotypes detected by EUROArray HPV in cervical samples among unvaccinated women from Vojvodina province, Serbia. PLoS One. 2021;16(4):e0249134. doi: 10.1371/journal.pone.0249134. PubMed DOI

Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121-6. DOI

Marić G, Birčanin Đ, Kisić V, Dotlić J, Zarić M, Kisić-Tepavčević D, et al. Parental perspective on human papillomavirus (HPV) vaccination in Serbia: knowledge, attitudes and practice. Sex Reprod Healthc. 2018;16:192-8. DOI

Hernandez BY, Ton T, Shvetsov YB, Goodman MT, Zhu X. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol. 2012;19(9):1348-52.

Okonko IO, Ofoedu V, Okerentugba PO, Frank-Peterside N. Seroepidemiology and high negativity of IgG antibodies against human papillomavirus (HPV) Type 6, 11, 16, and 18 virus-like particles in women of childbearing age in Port Harcourt, Nigeria. J Immunoassay Immunochem. 2015;36(2):210-20.

Faneye AO, Adeiga AA, Awoderu OB, Fayemiwo AS. Human papilloma virus vaccine awareness and vaccination history in patients attending STI clinics in Lagos and Ibadan, Nigeria. Arch Basic Appl Med. 2018;6(1):95-8.

Lu B, Hagensee ME, Lee JH, Wu Y, Stockwell HG, Nielson CM, et al. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev. 2010;19(2):511-6.

Du P, Brendle S, Milici J, Camacho F, Zurlo J, Christensen N, et al. Comparisons of VLP-based ELISA, neutralization assays with native HPV, and neutralization assays with PsV in detecting HPV antibody responses in HIV-infected women. J AIDS Clin Res. 2015;6(3):433. doi: 10.4172/2155-6113.1000433. PubMed DOI

Pinto LA, Dillner J, Beddows S, Unger ER. Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018;36(32 Pt A):4792-9. DOI

Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213(9):1444-54. DOI

Pruski D, Łagiedo-Żelazowska M, Millert-Kalińska S, Sikora J, Jach R, Przybylski M. Immunity after HPV vaccination in patients after sexual initiation. Vaccines (Basel). 2022;10(5):728. doi: 10.3390/vaccines10050728. PubMed DOI

Torjesen I. HPV vaccine cut cervical cancer rates in England by 87. BMJ. 2021;375:n2689. doi: 10.1136/bmj.n2689. PubMed DOI

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Serbia: summary report. Barcelona: HPV Information Centre; 2021.

Rancic NK, Miljkovic PM, Deljanin ZM, Marinkov-Zivkovic EM, Stamenkovic BN, Bojanovic MR, et al. Knowledge about HPV infection and the HPV vaccine among parents in southeastern Serbia. Medicina (Kaunas). 2022 Nov 22; 58(12):1697. doi: 10.3390/medicina58121697. PubMed DOI

[Rule book on immunization and the way of protection with medicines]. Službeni glasnik RS [Internet]. [cited 2020 Nov 29]. Available from: http://demo.paragraf.rs/WebParagrafDemo/?did=423949. Serbian.

Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis. 1996;173(6):1394-8. DOI

Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis. 2002;29(3):182-7. DOI

Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, et al. Seroconversion following anal and genital HPV infection in men: the HIM study. Papillomavirus Res. 2015;1:109-15. DOI